Current Position: Home >> NabLib®-Antibody Discovery Service >> Antibody Screening Platform

Mammal display platform

Category : Antibody Screening Platform • Last Updated : 2025-12-28 11:06:52 • Hits : 380

NBLST has developed proprietary gene expression technology that precisely restricts the integrated gene copy number per cell to one and tightly regulates the expression level of displayed targets within an appropriate range, preventing compromised screening accuracy caused by overexpression.

Mammalian cell display technology differs from other display technologies such as phage display and yeast display. It is an advanced platform engineered to optimize the druggability of therapeutic antibodies. This technology can not only be applied to antibody engineering represented by affinity maturation and humanization, but also be used for monoclonal antibody screening with superior sequence specificity.

Mammalian Cell Display Process：


Technical Advantages：





Mammalian cell display is a powerful antibody screening tool, which can effectively balance the library capacity and sequence specificity, and ensure the physicochemical properties of antibodies, thereby improving their pharmacability.

The mammalian display technology can not only be applied in the process of antibody screening, but also play a significant role in antibody engineering. It can be well adapted to humanization (or canine/feline source modification), affinity maturation, and PTM optimization, while maintaining excellent physicochemical properties.

Mammalian cell display technology is not only applicable to scFv or Fab-based antibodies, but also can efficiently display complex antibody structures such as full-length IgG, VHH, and TCR. It can even directly be used in the screening of antibodies in the form of bispecific antibodies, completing the one-step construction of bispecific antibodies and affinity adjustment in a seamless manner.

Screening of the full-spectrum configuration:


Mammalian cell display technology VS Other display technologies：


Representative cases 1：Discovery of Nanobodies - Balancing Affinity and Specificity

 The extracellular domains of CD16a and CD16b are highly homologous, with only 6 scattered amino acids differing. Nanobodies with high affinity for CD16a but not binding to CD16b were obtained through screening based on the display of antibodies in mammalian cells.

SPR

Flow cytometry



Representative cases 2：CD3 Nanobody Discovery

CD3 is a challenging target for drug development. Antibodies against CD3 are typically required to simultaneously exhibit cross-reactive binding to human and cynomolgus monkey CD3, cellular binding activity, and biological functions such as agonistic activity. As a core component of therapeutics including CAR-T, bispecific antibodies and T cell engagers (TCEs), CD3 antibodies demand tailored affinity profiles based on specific application scenarios. Accordingly, custom antibody discovery services represent the optimal route to generate CD3-targeted antibodies: such services enable combinatorial screening of bispecific or TCE constructs using antibody molecules with varying affinities and agonistic potency to identify the optimal functional combination while meeting all project requirements.
Leveraging its mammalian cell display platform, Nabo Life Sciences employs cell-based enrichment coupled with a full eukaryotic expression screening workflow to isolate CD3 nanobodies possessing all the aforementioned functional activities.

ELISA

Flow cytometry & Agonistic activity





Prev Not Available
Next Nabphage Improved phage display